Thyroid Cancer
📧 Sign up to get email alerts when something new happens for Thyroid Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-11-20FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for RETEVMO (selpercatinib) submitted by Eli Lilly and Company, expanding its approved indicatio…
-
FDA approval · 2024-12-18FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for RETEVMO (selpercatinib) by Eli Lilly, expanding its approved indications for RET fusion-positive…
-
FDA approval · 2024-04-10FDA Approved: RETEVMO — Original Application (Eli Lilly and Company)
The FDA approved the original application for selpercatinib (RETEVMO) from Eli Lilly and Company. It is approved for RET fusion-positive non…
-
FDA approval · 2023-07-21FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for Levothyroxine Sodium, a generic product used to treat hypothyroidism and re…
-
FDA approval · 2021-11-10FDA Approved: GAVRETO — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Gavreto (pralsetinib) filed by Genentech, expanding its label for RET fusion–positive cancer…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-11-05FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Levothyroxine Sodium from Mylan Pharmaceuticals under an ANDA, authorizing the change descri…
-
FDA approval · 2020-09-04FDA Approved: GAVRETO — Original Application (Genentech, Inc.)
The FDA approved Gavreto (pralsetinib) from Genentech as an original application for treating metastatic RET fusion-positive cancers, includ…
-
FDA approval · 2020-03-12FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for THYROGEN (thyrotropin alfa) from Genzyme Corporation, updating the labeling to support its use i…
-
FDA approval · 2020-02-05FDA Approved: SODIUM IODIDE I-131 — Original Application (Radnostix, Inc.)
FDA approved the original application for Sodium Iodide I-131 (Radnostix, Inc.), a radiopharmaceutical used to treat hyperthyroidism and thy…
-
FDA approval · 2019-06-03FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for Levothyroxine Sodium from Lupin Pharmaceuticals, Inc. This action updates the product's labeling…
-
FDA approval · 2019-04-23FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Alvogen, Inc.)
FDA approved a supplemental application for Levothyroxine Sodium (Alvogen, Inc.), authorizing changes to the product labeling.
-
FDA approval · 2017-12-08FDA Approved: TIROSINT — Supplemental Application (IBSA Pharma Inc.)
The FDA approved a supplemental application for TIROSINT (levothyroxine sodium) by IBSA Pharma Inc., updating the product labeling as part o…
-
FDA approval · 2017-01-12FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lannett Company, Inc)
The FDA approved a supplemental application for Levothyroxine Sodium from Lannett Company, Inc, enabling the marketed generic product.
-
FDA approval · 2016-07-08FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)
FDA approved a supplemental application for HICON (Sodium Iodide I-131) from Jubilant Radiopharma.
-
EMA approval · 2015-03-27Accelerated assessment fast-tracks Lenvima to benefit patients with thyroid cancer
The European Medicines Agency granted accelerated assessment for Lenvima, speeding its evaluation to benefit patients with thyroid cancer.
-
FDA approval · 2014-05-06FDA Approved: LEVOXYL — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for LEVOXYL (levothyroxine sodium) submitted by Pfizer Laboratories Div Pfizer Inc. The action repre…
-
FDA approval · 2013-05-07FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for THYROGEN (thyrotropin alfa) from Genzyme Corporation.
-
FDA approval · 2011-10-03FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)
FDA approved a supplemental application for HICON (Sodium Iodide I-131) from Jubilant Radiopharma, updating the product labeling to reflect …
-
FDA approval · 2011-09-23FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)
The FDA approved a supplemental application for HICON (Sodium Iodide I-131) from Jubilant DraxImage Inc., dba Jubilant Radiopharma. The appr…
-
FDA approval · 2011-03-09FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lannett Company, Inc)
FDA approved the supplemental application for Levothyroxine Sodium from Lannett Company, Inc, authorizing the marketing of this generic prod…
-
FDA approval · 2008-10-30FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for levothyroxine sodium from Mylan Pharmaceuticals Inc., granting regulatory approval for this gene…
-
FDA approval · 2008-06-10FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lannett Company, Inc)
The FDA approved a supplemental application for levothyroxine sodium submitted by Lannett Company, Inc., authorizing continued marketing of …